Research With A Heart
To provide culturally competent research on HIV treatment and prevention through community engagement, collaboration, and education.
Rutgers New Jersey Medical School Clinical Research Center (NJMS CRC) is conveniently located within the Infectious Disease Practice in Newark, NJ. We are one of only two sites funded by the Division of AIDS (DAIDS), National Institutes of Health (NIH) in the state of New Jersey and have been a research site for over 20 years. To date, we have have successfully enrolled over 1,000 participants. Research studies conducted at the NJMS CRC range from HIV prevention and treatment to management of HIV related comorbidities and complications in men, women and the LGBTQ community.
In addition to HIV studies, our site also participates in Hepatitis C and influenza trials. Studies are either industry funded or investigator initiated and are sponsored by one or more of the following organizations: the National Institutes of Health (NIH), DAIDS, AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).
Clinical research is an essential tool used to help improve treatment and quality care of patients. At NJMS CRC we strive to provide our community with the highest quality research and encourage participation in our cutting edge research program.
We ARE Research With A Heart
Check out below to see some of our current studies!
People with HIV are living longer thanks to lifesaving treatments, but as they age, they can face new complications like HIV-related heart disease. The REPRIEVE trial confronts this emerging challenge to learn how people with HIV can live in good health even longer.
For more information, please check out www.reprievetrial.org or
contact us at 973-972-3811.
HPTN083 is a research study that compares the effectiveness of injections and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV.
AMP stands for Antibody Mediated Prevention. This is the idea of giving people antibodies to see if they will protect against HIV infection. This study, also referred to as HVTN 704/HPTN 085, tests a new idea for HIV prevention. In traditional vaccine studies, we give people a vaccine and wait to see if their bodies will make antibodies against HIV in response. In this study, we’ll be skipping that step, and just giving people the antibodies directly. We will do this through an infusion, which some people know better as getting an IV or getting a drip. This is the first study testing whether this antibody can prevent HIV infections in people.
Want to learn more about what we do?